within Pharmacolibrary.Drugs.ATC.G;

model G03BB02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.02,
    adminDuration  = 600,
    adminMass      = 0.05,
    adminCount     = 1,
    Vd             = 0.015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Androstanolone (also known as dihydrotestosterone, DHT) is a potent natural androgen and a metabolite of testosterone. It is primarily used in androgen replacement therapy for male hypogonadism and has also been used in the treatment of certain forms of anemia, breast cancer, and as part of hormone therapy. Its clinical use is limited today and it is not widely approved or prescribed due to availability of other safer or more effective androgenic drugs.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are estimated based on published aggregate data in healthy adult males following parenteral (intramuscular) administration. No human population pharmacokinetic modeling studies with primary parameters for androstanolone found in literature.</p><h4>References</h4><ol><li><p>Saudan, C, et al., &amp; Saugy, M (2006). Testosterone and doping control. <i>British journal of sports medicine</i> 40 Suppl 1(Suppl 1) i21–i24. DOI:<a href=&quot;https://doi.org/10.1136/bjsm.2006.027482&quot;>10.1136/bjsm.2006.027482</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16799097/&quot;>https://pubmed.ncbi.nlm.nih.gov/16799097</a></p></li><li><p>Edelstein, D, et al., &amp; Basaria, S (2007). The latest options and future agents for treating male hypogonadism. <i>Expert opinion on pharmacotherapy</i> 8(17) 2991–3008. DOI:<a href=&quot;https://doi.org/10.1517/14656566.8.17.2991&quot;>10.1517/14656566.8.17.2991</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18001258/&quot;>https://pubmed.ncbi.nlm.nih.gov/18001258</a></p></li><li><p>Dowsett, M, et al., &amp; Coombes, RC (1989). Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostenedione in postmenopausal breast cancer patients. <i>Cancer research</i> 49(5) 1306–1312. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2917360/&quot;>https://pubmed.ncbi.nlm.nih.gov/2917360</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G03BB02;
